Zoetis Craters to 2017 Levels, But Is It Worth Buying?

What happened

Zoetis shares have collapsed 71% from their 2021 peak, now trading at levels last seen in 2017, as pricing power erodes and volumes of key pet medicines decline. Despite these headwinds, the company retains industry-leading gross margins above 70% and a strong balance sheet, which management argues position it to outlast rivals in a price war. Key risks include the 2030 and 2032 patent expiries for Apoquel and Simparica, which together represent roughly a quarter of revenue, though a pipeline of 12 candidates offers potential offset if half succeed. The deep value report had previously rated ZTS a WAIT with an attractive entry of $110 and base case value of $135, citing moderating growth and thin margin of safety at $125. The new article suggests the market may have overcorrected, but the erosion of pricing power and volumes aligns with existing bear concerns, so the discount may reflect real deterioration rather than mere sentiment.

Implication

The sharp decline may have expanded the margin of safety if the stock now trades below the previously identified $110 attractive entry, but that alone does not warrant a purchase given unresolved questions about OA mAb safety and competitive pressures. The article’s emphasis on pricing power erosion and volume declines suggests the core growth engine is weakening, which could compress margins further despite current high levels. Patent expiries in 2030/2032 are distant but will eventually force the company to replace a large share of revenue, and the pipeline’s success probability is uncertain. Investors should monitor upcoming quarterly reports for signs of stabilization in companion-animal volumes and pricing, as well as any updates on Librela and Solensia safety data, before committing capital. A disciplined approach would be to wait for either a clear inflection in fundamentals or a price that compensates for the increased uncertainty, which the current article does not convincingly establish.

Thesis delta

The prior thesis rated ZTS a WAIT at $124.82, citing limited upside and thin margin of safety. The new article reports a much lower price, potentially below the $110 attractive entry, which would improve the risk-reward, but it provides no new financial details to confirm whether the decline is due to temporary overreaction or structural deterioration. Consequently, the thesis shifts only slightly toward a potential buy on weakness, contingent on verifying that the company’s competitive position and pricing power have not permanently impaired.